Preferred Label : Sotiburafusp Alfa;
NCIt synonyms : Anti-PD-L1 Monoclonal Antibody/VEGFR1 Fusion Protein HB0025; Anti-PD-L1/VEGFR-1 Fusion Protein HB0025;
NCIt definition : A recombinant, humanized fusion protein composed of a monoclonal antibody directed
against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster
of differentiation 274; CD274) fused to vascular endothelial growth factor receptor
1 (VEGFR-1/FLT-1), with potential anti-angiogenesis, immune checkpoint inhibitory
and antineoplastic activities. Upon administration of sotiburafusp alfa, the anti-PD-L1
antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor
microenvironment (TME). In turn, VEGFR-1 moiety binds to pro-angiogenic vascular endothelial
growth factors (VEGFs), thereby preventing VEGFs from binding to the endogenous receptors.
Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition
of tumor angiogenesis and metastasis, and ultimately tumor regression. PD-L1, a transmembrane
protein, is expressed on the surface of antigen presenting cells (APCs) and on many
cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system
on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses
the immune system and results in immune evasion.;
UNII : 34DTV38QW5;
CAS number : 2637466-37-4;
Molecule name : HB-0025; HB 0025;
NCI Metathesaurus CUI : CL1662405;
Origin ID : C179665;
UMLS CUI : C5854871;
Semantic type(s)
- concept_is_in_subset
- has_target
